Blockbuster drugs such as Forest Laboratories’ Lexapro and Pfizer’s Lipitor are due to lose patent protection in the next few years, allowing less-costly generic versions to go on the market. Generic drugs account for approximately 70 percent of all prescriptions dispensed. As more blockbuster drugs lose their patents and healthcare reformers push for more cost-reducing solutions, generic medications will continue to be an important part of the prescription drug market.
Brocair Partners LLC, an investment bank serving the healthcare industry, has published a new report on the generic pharmaceuticals sector. The Brocair report contains a matrix of the indications addressed by companies that compete in this sector, an overview of industry participants, profiles of selected companies, a market and valuation analysis, and an overview of recent corporate transactions. The report can be downloaded here.